A nuclear antagonistic mechanism of inhibitory Smads in transforming growth factor-β signaling

被引:91
|
作者
Bai, ST [1 ]
Cao, X [1 ]
机构
[1] Univ Alabama, Sch Med, Dept Pathol, Birmingham, AL 35294 USA
关键词
D O I
10.1074/jbc.M105105200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Inhibitory Smads (I-Smads), including Smad6 and Smad7, were initially characterized as cytoplasmic antagonists in the transforming growth factor-beta signaling pathway. However, I-Smads are also localized in the nucleus. Previously, we have shown that Smad6 can function as a transcriptional co-repressor. In this study, we found both Smad6 and Smad7 interact with histone deacetylases (HDACs). Acetylation state of core histones plays a critical role in gene transcription regulation. An HDAC inhibitor, trichostatin A, released Smad6-mediated transcription repression. Moreover, class I HDACs (HDAC-1 and -3), not class II HDACs (HDAC-4,-5, and -6), were co-immunoprecipitated with Smad6. Endogenous HDAC-1 was also shown to interact with both Smad6 and Hoxc-8. Mapping of the interaction domain indicates Smad6 MH2 domain is mainly involved in recruiting HDAC-1. Most interestingly, Smad6 also binds to DNA through its MH1 domain, and the MH2 domain of Smad6 masks this binding activity, indicating that Smad6 MH1 and MR2 domains associate reciprocally and inhibit each other's function. Hoxc-8 induces Smad6 binding to DNA as a transcriptional complex. Our findings revealed that I-Smads act as antagonists in the nucleus by recruiting HDACs.
引用
收藏
页码:4176 / 4182
页数:7
相关论文
共 50 条
  • [1] Transforming Growth Factor-β and Smads
    Lan, Hui Yao
    Chung, Arthur C. K.
    [J]. DIABETES AND THE KIDNEY, 2011, 170 : 75 - 82
  • [2] Smads are the central-component in transforming growth factor-β signaling
    Padgett, RW
    Cho, SH
    Evangelista, C
    [J]. PHARMACOLOGY & THERAPEUTICS, 1998, 78 (01) : 47 - 52
  • [3] Filamin associates with Smads and regulates transforming growth factor-β signaling
    Sasaki, A
    Masuda, Y
    Ohta, Y
    Ikeda, K
    Watanabe, K
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (21) : 17871 - 17877
  • [4] Transforming growth factor-β, smads, and cancer
    Grady, WM
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (09) : 3151 - 3154
  • [5] Role of Transforming Growth Factor-β1 and Smads Signaling Pathway in Intrauterine Adhesion
    Salma, Umme
    Xue, Min
    Sheikh, Md Sayed Ali
    Guan, Xiaoming
    Xu, Bin
    Zhang, Aiqian
    Huang, Lihua
    Xu, Dabao
    [J]. MEDIATORS OF INFLAMMATION, 2016, 2016
  • [6] Choosing Smads Smooth Muscle Origin-Specific Transforming Growth Factor-β Signaling
    Majesky, Mark W.
    [J]. CIRCULATION RESEARCH, 2013, 113 (08) : 946 - 948
  • [7] Nodal signaling uses activin and transforming growth factor-β receptor-regulated smads
    Kumar, A
    Novoselov, V
    Celeste, AJ
    Wolfman, NM
    ten Dijke, P
    Kuehn, MR
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (01) : 656 - 661
  • [8] Effects of danshensu on the transforming growth factor-β1/smads signaling pathway in rats with lung injury
    Qin, Jing
    Zhang, Xiaoqiang
    Wang, Shengyan
    Zhang, Yongming
    [J]. MATERIALS EXPRESS, 2020, 10 (11) : 1816 - 1823
  • [9] Wnt/β-Catenin and Transforming Growth Factor-β Signaling in Pulmonary Fibrosis A Case for Antagonistic Pleiotropy?
    Scheraga, Rachel G.
    Thannickal, Victor J.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 190 (02) : 129 - 131
  • [10] Transforming growth factor-β signaling in cancer
    Rich, JN
    Borton, AJ
    Wang, XF
    [J]. MICROSCOPY RESEARCH AND TECHNIQUE, 2001, 52 (04) : 363 - 373